Fulcrum Therapeutics, Inc. Segments Disclosure
18. Segment Information
Segment reporting is prepared on the same basis that the Company's chief executive officer, who is the Company's chief operating decision maker (the “CODM”), utilizes to manage the business and makes decisions on how to allocate resources and assess performance of the business. The Company and the CODM view the Company's operations as a single operating segment. The Company's singular focus is on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need.
The Company and the CODM primarily utilize the segment's consolidated net loss, disaggregated between (a) research and development and (b) general and administrative, as the key indicator to assess the segment's performance and for allocating resources.
The Company's reportable segment revenue, operating expenses, and net loss for the years ended December 31, 2025 and December 31, 2024 are as follows:
|
|
Year Ended |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Collaboration Revenue |
|
|
— |
|
|
|
80,000 |
|
Operating expenses: |
|
|
|
|
|
|
||
Research and development |
|
|
|
|
|
|
||
Pociredir external expenses |
|
|
19,994 |
|
|
|
8,577 |
|
Losmapimod external expenses |
|
|
941 |
|
|
|
20,801 |
|
Employee compensation expenses (excluding stock-based compensation expenses) |
|
|
12,659 |
|
|
|
15,347 |
|
Stock-based compensation expenses |
|
|
3,448 |
|
|
|
4,653 |
|
Pre-development candidate expenses and unallocated expenses |
|
|
19,061 |
|
|
|
14,008 |
|
General and administrative |
|
|
28,666 |
|
|
|
36,448 |
|
Restructuring expenses |
|
|
— |
|
|
|
2,063 |
|
Total operating expenses |
|
|
84,769 |
|
|
|
101,897 |
|
Loss from operations |
|
|
(84,769 |
) |
|
|
(21,897 |
) |
Other income, net |
|
|
9,889 |
|
|
|
12,172 |
|
Net loss |
|
$ |
(74,880 |
) |
|
$ |
(9,725 |
) |
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 24, 2026 | Showing above |
| 2024 | Feb 25, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.